Ponatinib (Pon) in Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (All).

Trial Profile

Ponatinib (Pon) in Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (All).

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Expanded access; Therapeutic Use
  • Acronyms OPAL observatory
  • Most Recent Events

    • 21 Jul 2017 New trial record
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top